The Access for All in ALS (ALL ALS) Consortium has announced enrollment of its 1,000th participant, marking a major milestone for what is designed to be the largest and most inclusive prospective observational biobanking study in ALS.
The 1,000th participant was enrolled at the University of Utah, under the leadership of Principal Investigator Mark Bromberg, MD. “ALL ALS is an extremely important study to better understand what is behind ALS, and our clinical trials group is very pleased to have been the clinic to reach this milestone in enrollment. We look forward to adding to enrollment and contributing to the ultimate goal of finding effective treatments for ALS,” said Mark Bromberg, MD, PhD, the Chief of the Division of General Neurology at the University of Utah.
The ALL ALS Consortium launched in 2023 with funding from the National Institutes of Health (NIH), bringing together 36 clinical research sites across the United States and two coordination centers led by researchers at Barrow Neurological Institute and Massachusetts General Hospital. ALL ALS enrolls participants with ALS, those genetically at-risk for developing ALS, and controls.